Poster in the 13th International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders

Avidin is presenting a poster in collaboration with Sanders-Brown Center on Aging, University of Kentucky at the AD/PDTM 2017 meeting, the 13th International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders on Thursday, March 30, 2017. Poster: Presentation number: 138 Authors: Christopher M. Norris, Susan D. Kraner, Melanie M. Pleiss, Pradoldej Sompol, Irina A. Artiushin, Orsolya Huzian, Laszlo …

Strategic Changes in the Pipeline

Today Avidin anounced that the company has made extensive recostruction of its projects. The R&D pipeline has changed and become updated accordingly (http://avidinbiotech.com/pipeline/). Q134R, Avidin’s most advanced program has entered into Phase 1a clinical trial, and its back-up compound, QPA-2203 reaches final stages in optimization.  The C-509 program has been halted for oncology indications, while two additional drug development programs …

Approval to a Phase 1 Clinical Study

Approval to Initiate a Phase 1, First–In-Man, Clinical Study for Q134R Soneas Research Ltd. in collaboration with Avidin received approval to initiate a Phase 1, First–In-Man, clinical study for Q134R. Q134R is a potent, selective, orally available small molecule that is brain penetrant and showed good toxicity and metabolic stability profile in preclinical studies. Q134R exhibited neuroprotective and cognitive enhancing …

BIO International Convention

Meet AVIDIN in San Francisco at the BIO International Convention between  June 6-9 2016.  Our CEO and Head of International Relations are looking forward to meet you during the conference to explore possible synergies. Schedule a meeting in the parntering system.

New Product: Luciferin ethyl ester

Avidin has optimized the synthesis of  Luciferin ethyl ester, a membrane permeable analog of the primary substrate for the firefly luciferase. This reagent produces 30% higher light intensity than the parent compound. It is especially suited for sensitive detection of luciferase expressing cells in tissues and in vivo animal studies. Our solubilization buffer, provided to each ordered reagent, enables this …

Successful H2020 grant

Avidin as part of a European consortium leaded by the Burgos University (Spain) successfully won a H2020 grant (PHC-14-2015) entitled „Novel therapeutic approaches for the treatment of cystic fibrosis based on small molecule transmembrane anion transporters” (Project acronym: TAT-CF). The project will develop an innovative therapeutic approach for the treatment of Cystic Fibrosis (CF) by evaluating small molecules capable of …

AVIDIN’s Miniconference & Workshop

MINICONFERENCE & WORKSHOP Avidin organized a Miniconference & Workshop entitled “TOP LIFE SCIENCE METHODS – Label-free and traditional methods to analyze cellular response to natural and drug-like compounds” at Avidin’s headquarters on 6th July 2015. More than 30 participants, including university students, post-docs and senior scientists took theoretical and practical courses on traditional biochemical and FACS methods, 3D cell cultures …

New Product – SingleCellProtect

SingleCellProtectTM (Cat# SCP-50, SCP-250) solution is an aqueous, nontoxic reagent that induces cell lysis, stabilizes and protects cellular RNA. It is compatible with reverse transcription, ligation, DNA polymerase reactions, therefore the application of SingleCellProtectTM is highly recommended for single cell genomics technologies (single cell PCR, next generation sequencing, multiplex gene expression analysis, etc.). Further information

New Products – MycoKill, MycoQuant

In cell culturing mycoplasma contamination is a major problem regarding both research and industrial production. Unlike fungal or bacterial infections, mycoplasmal contaminations cannot be detected by visual inspection, but can lead to unreliable experimental results and potential unsafe biological products. Avidin provides solutions for sensitive detection of  mycoplasma infection from cell culture supernatants, cells and body fluids, as well as offers …

New Patent by IP Australia

New patent, entitled ‘8 Hidroxy-Quinoline Derivatives’ was granted by the Australian Patent Office under patent number 2011256989 on 4th December 2014.